ANG Lifesciences India (BOM:540694) Stock Based Compensation: ₹0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540694 ANG Lifesciences India Ltd BOM:540694
64 GF Score
Price ₹31.42
GF Value ₹30.08
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is ANG Lifesciences India Stock Based Compensation?

ANG Lifesciences India BOM:540694 64 Stock Based Compensation is ₹0.0 Mil as of Mar. 2026. GuruFocus rates BOM:540694 with a GF Score™ of 64/100 and a GF Value™ of ₹30.08 (Fairly Valued). The stock has 3 warning signs investors should review.

ANG Lifesciences India's Stock Based Compensation for the three months ended in Mar. 2026 was ₹0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

ANG Lifesciences India Stock Based Compensation Related Terms

ANG Lifesciences India Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for ANG Lifesciences India's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANG Lifesciences India Stock Based Compensation Chart

ANG Lifesciences India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANG Lifesciences India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:540694
64GF Score
ANG Lifesciences India Ltd BOM:540694
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANG Lifesciences India Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

What does a Stock Based Compensation of ₹0.0 Mil mean?
ANG Lifesciences India (BOM:540694) has a Stock Based Compensation of ₹0.0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ANG Lifesciences India and its competitors.
Is ANG Lifesciences India's Stock Based Compensation too high?
ANG Lifesciences India's current Stock Based Compensation is ₹0.0 Mil. Overall, ANG Lifesciences India has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's Stock Based Compensation compare to ZTS?
ANG Lifesciences India's Stock Based Compensation of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ANG Lifesciences India and its competitors. ANG Lifesciences India's current Stock Based Compensation is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Fairly Valued. The stock's GF Value™ is ₹30.08, compared to a current price of ₹31.42 — trading 4.5% above its estimated fair value. The current Stock Based Compensation is ₹0.0 Mil. ANG Lifesciences India's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current Stock Based Compensation is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?

Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued. The current stock price of ₹31.42 is trading 4.5% above its estimated GF Value™ of ₹30.08. GuruFocus considers ANG Lifesciences India to be Fairly Valued.

Key valuation signals for BOM:540694:

  • Stock Based Compensation: ₹0.0 Mil
  • GF Value™: ₹30.08 vs. price of ₹31.42 (4.5% above fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANG Lifesciences India Business Description

Address Ranjit Avenue, B-Block, Darbara Complex, SCO 113, First Floor, District Shopping Complex, Amritsar, PB, IND, 143001
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
64GF Score

Get the complete analysis for BOM:540694

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹31.42
Price
₹30.08
GF Value